Valuation : Alkermes plc

Market Cap 773.39Cr 665.11Cr 625.56Cr 571.05Cr 1.07TCr 73TCr 1.07TCr 7.42TCr 2.87TCr 37TCr 2.9TCr 2.84TCr 1,19300Cr P/E 2026 *
-90.4x
P/E 2027 * 63.4x
Enterprise Value 847.78Cr 729.09Cr 685.74Cr 625.98Cr 1.17TCr 80TCr 1.17TCr 8.13TCr 3.14TCr 41TCr 3.18TCr 3.11TCr 1,30800Cr EV / Sales 2026 *
4.65x
EV / Sales 2027 * 4.32x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week-2.37%
Current month-1.94%
1 month-6.72%
3 months+8.55%
6 months+61.97%
Current year+64.69%
1 week 44.63
Extreme 44.63
48.74
1 month 44.63
Extreme 44.63
51.66
Current year 27
Extreme 27
55.67
1 year 26.4
Extreme 26.4
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Sell

Compliance Officer

-2,034 0.0012%
01/09/26 Exercice

Chief Technology Officer

19,000 0.0113%
17/08/26 Sell

Executive/Senior Manager

-7,576 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-2.37%+61.97%+59.72% 773.39Cr
-0.23%-3.46%-2.17%+15.30% 4.84TCr
+0.96%+0.25%+412.41%+555.03% 4.5TCr
-2.37%+0.90%+38.89%+22.08% 4.41TCr
-3.63%-3.40%+0.00%+79.86% 4.07TCr
-0.96%-1.38%+15.75%+45.91% 3.32TCr
-0.30%+3.47% - - 1.78TCr
-0.30%+1.06%+19.77%+117.40% 1.65TCr
-0.36%-0.36%+11.55%+31.60% 1.45TCr
-2.55%-0.31%+73.74%+40.92% 1.38TCr
Average -1.02%-0.02%+70.21%+107.53% 2.82TCr
Weighted average by Cap. -1.14%-0.10%+85.96%+132.23%

Financials

2026 *2027 *
Net sales 182.49Cr 156.94Cr 147.61Cr 134.75Cr 252.01Cr 17TCr 252.82Cr 1.75TCr 676.51Cr 8.84TCr 685.33Cr 670.34Cr 28TCr 194.48Cr 167.26Cr 157.31Cr 143.6Cr 268.57Cr 18TCr 269.44Cr 1.87TCr 720.97Cr 9.42TCr 730.37Cr 714.4Cr 30TCr
Net income -8.99Cr -7.73Cr -7.27Cr -6.64Cr -12Cr -850.4Cr -12Cr -86Cr -33Cr -435.49Cr -34Cr -33Cr -1.39TCr 12Cr 10Cr 9.73Cr 8.88Cr 17Cr 1.14TCr 17Cr 115.36Cr 45Cr 582.57Cr 45Cr 44Cr 1.86TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 102.73Cr 7.04TCr 103.06Cr 713.45Cr 275.78Cr 3.6TCr 279.37Cr 273.26Cr 11TCr 67Cr 58Cr 54Cr 49Cr 93Cr 6.34TCr 93Cr 642.49Cr 248.35Cr 3.24TCr 251.58Cr 246.08Cr 10TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
08/26/08 $46.12 +0.03% 3,64,399
04/26/04 $46.10 -1.66% 10,64,034
03/26/03 $46.88 -1.76% 9,74,512
02/26/02 $47.72 +1.10% 15,66,413
01/26/01 $47.20 +0.45% 13,51,261
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
46.10USD
Average target price
56.00USD
Spread / Average Target
+21.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!